Australia markets closed

Eagle Pharmaceuticals, Inc. (EGRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.95+0.10 (+1.71%)
At close: 04:00PM EST
6.20 +0.25 (+4.20%)
After hours: 07:59PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 77.01M
Enterprise value 133.27M
Trailing P/E 6.98
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.30
Price/book (mrq)0.31
Enterprise value/revenue 0.52
Enterprise value/EBITDA 2.38

Trading information

Stock price history

Beta (5Y monthly) 0.83
52-week change 3-82.48%
S&P500 52-week change 314.90%
52-week high 335.82
52-week low 35.53
50-day moving average 312.29
200-day moving average 319.85

Share statistics

Avg vol (3-month) 3138.63k
Avg vol (10-day) 3311.84k
Shares outstanding 512.99M
Implied shares outstanding 612.99M
Float 811.48M
% held by insiders 113.24%
% held by institutions 190.41%
Shares short (14 Nov 2023) 4594.6k
Short ratio (14 Nov 2023) 45.47
Short % of float (14 Nov 2023) 47.09%
Short % of shares outstanding (14 Nov 2023) 44.58%
Shares short (prior month 12 Oct 2023) 4602.89k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 June 2023


Profit margin 4.64%
Operating margin (ttm)15.94%

Management effectiveness

Return on assets (ttm)6.63%
Return on equity (ttm)4.88%

Income statement

Revenue (ttm)257.55M
Revenue per share (ttm)19.68
Quarterly revenue growth (yoy)-12.80%
Gross profit (ttm)221.67M
Net income avi to common (ttm)11.95M
Diluted EPS (ttm)0.85
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)15.35M
Total cash per share (mrq)1.18
Total debt (mrq)72.45M
Total debt/equity (mrq)28.75%
Current ratio (mrq)2.16
Book value per share (mrq)19.25

Cash flow statement

Operating cash flow (ttm)-9.32M
Levered free cash flow (ttm)38.31M